CompoundIQ

Disclaimer

CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.

OtherBeginnerLow Risk

NMN (Nicotinamide Mononucleotide)

Also known as: NMN, Nicotinamide Mononucleotide, Beta-NMN

NMN is a nucleotide that serves as a direct precursor to NAD+ (nicotinamide adenine dinucleotide). NAD+ levels decline significantly with age, and restoring them is hypothesized to reverse aspects of aging. Popularized by Harvard researcher David Sinclair, NMN has become one of the most popular longevity supplements despite limited human clinical data.

Evidence45/100 — Emerging

Risk Level

Low Risk

Difficulty

Beginner
CAS Number1094-61-7
Molecular FormulaC11H15N2O8P
ClassOther
CategoryLongevity Compounds

Mechanism of Action

NMN is converted to NAD+ via the enzyme nicotinamide mononucleotide adenylyltransferase (NMNAT). Elevated NAD+ activates sirtuins (SIRT1-7), a family of NAD+-dependent deacetylases that regulate DNA repair, mitochondrial function, inflammation, and circadian rhythm. NAD+ also supports PARP-mediated DNA repair and CD38-related immune function. Restoring youthful NAD+ levels may improve mitochondrial function and cellular resilience.

Dosing Research

Common doses: 250-1000 mg/day orally. Some protocols use sublingual administration for improved bioavailability. Often taken in the morning due to potential circadian effects. No established optimal dose. Human studies have used 250-900 mg/day. Some users combine with resveratrol and TMG (trimethylglycine) as a methyl donor.

Side Effects & Risks

Generally well-tolerated in human studies. Mild GI discomfort reported by some. Theoretical concern about promoting growth of existing cancers via enhanced NAD+ metabolism (no evidence in humans). May cause flushing at high doses. Long-term safety data in healthy humans is limited. FDA considered banning as supplement in 2022.

Research Studies

Disclaimer

CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.

Send Feedback

Help us improve CompoundIQ